Myosin

Compared with placebo, aficamten was associated with increased exercise capacity and improvements in symptoms of obstructive hypertrophic cardiomyopathy, according to topline results of the phase 3 SEQUOIA-HCM trial.

In patients with symptomatic obstructive hypertrophic cardiomyopathy, mavacamten was linked with improved cardiac structure and function compared with placebo, according to new data from the EXPLORER-HCM trial.

Aficamten (Cytokinetics) in patients with hypertrophic cardiomyopathy and elevated LV outflow tract.

Aficamten, a novel selective cardiac myosin inhibitor, was associated with improvements in HF symptoms and hemodynamics at 10 weeks, according to a phase 2 study presented at the Heart Failure Society of America Annual Scientific Meeting.

Cytokinetics announced a phase 2 trial of its novel cardiac myosin inhibitor in patients with obstructive hypertrophic cardiomyopathy was successful.

The treatment effect of omecamtiv mecarbil in patients with HF rose as left ventricular ejection fraction declined, according to new data from the GALACTIC-HF trial presented at the American College of Cardiology Scientific Session.

The cardiac myosin inhibitor mavacamten substantially improved health status in patients with symptomatic obstructive hypertrophic cardiomyopathy, with benefits observed early after treatment, according to new data from EXPLORER-HCM.

Mavacamten improved left ventricular hypertrophy, decreased measures of heart stiffness and restored normal mitral valve motion in patients with obstructive hypertrophic cardiomyopathy, according to an analysis of the EXPLORER-HCM trial.

MyoKardia announced that the FDA has granted breakthrough therapy designation to mavacamten for the treatment of patients with symptomatic, obstructive hypertrophic cardiomyopathy.

Danicamtiv, a novel cardiac myosin activator, improved left ventricular systolic function and left atrial volume and function for patients with HF with reduced ejection fraction in a phase 2a trial.